25 XP   0   0   10

Yifan Xinfu Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Yifan Xinfu Pharmaceutical Co Ltd together

PenkeI guess you are interested in Yifan Xinfu Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Yifan Xinfu Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Yifan Xinfu Pharmaceutical Co Ltd

I send you an email if I find something interesting about Yifan Xinfu Pharmaceutical Co Ltd.

Quick analysis of Yifan Xinfu Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Yifan Xinfu Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.04
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
¥7.46
Expected worth in 1 year
¥8.86
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
¥1.68
Return On Investment
14.0%

For what price can you sell your share?

Current Price per Share
¥12.02
Expected price per share
¥10.74 - ¥12.99
How sure are you?
50%

1. Valuation of Yifan Xinfu Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥12.02

Intrinsic Value Per Share

¥-4.22 - ¥1.30

Total Value Per Share

¥3.24 - ¥8.76

2. Growth of Yifan Xinfu Pharmaceutical Co Ltd (5 min.)




Is Yifan Xinfu Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1.2b$1.2b$51.3m4.1%

How much money is Yifan Xinfu Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$26.4m$38.4m-$12m-45.5%
Net Profit Margin5.0%6.3%--

How much money comes from the company's main activities?

3. Financial Health of Yifan Xinfu Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Yifan Xinfu Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Yifan Xinfu Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Yifan Xinfu Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Yifan Xinfu Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Yifan Xinfu Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Yifan Xinfu Pharmaceutical Co Ltd is ¥12.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Yifan Xinfu Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Yifan Xinfu Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.46. Based on the TTM, the Book Value Change Per Share is ¥0.35 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.07 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Yifan Xinfu Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.020.2%0.020.2%0.030.3%0.070.6%0.060.5%
Usd Book Value Change Per Share0.050.4%0.050.4%0.010.0%0.050.4%0.100.8%
Usd Dividend Per Share0.010.1%0.010.1%0.020.1%0.020.2%0.020.1%
Usd Total Gains Per Share0.060.5%0.060.5%0.020.2%0.080.6%0.110.9%
Usd Price Per Share1.69-1.69-2.43-2.09-2.72-
Price to Earnings Ratio78.52-78.52-78.11-44.16-152.04-
Price-to-Total Gains Ratio29.13-29.13-116.43-41.50-83.56-
Price to Book Ratio1.64-1.64-2.48-2.25-9.84-
Price-to-Total Gains Ratio29.13-29.13-116.43-41.50-83.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.659962
Number of shares602
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.02
Usd Book Value Change Per Share0.050.05
Usd Total Gains Per Share0.060.08
Gains per Quarter (602 shares)34.9646.95
Gains per Year (602 shares)139.83187.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12311613060128178
247233270119256366
370349410179385554
494466550238513742
5117582690298641930
61416988303577691118
71648159704178981306
8187931111047610261494
92111048125053611541682
102341164139059612821870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.02.090.9%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.03.00.086.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%19.00.03.086.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.02.00.090.9%

Fundamentals of Yifan Xinfu Pharmaceutical Co Ltd

About Yifan Xinfu Pharmaceutical Co Ltd

Yifan Pharmaceutical Co., Ltd. engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. It offers oral slow controlled release preparations, micron suspensions, micelles for injection, and liquid preparations. The company also focuses on hematologic maliganancies, inflammatory, endocrinology/metabolic, dermatological, gynecologic, and pediatric diseases, etc. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.

Fundamental data was last updated by Penke on 2024-04-14 12:18:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Yifan Xinfu Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Yifan Xinfu Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 5.0% means that ¥0.05 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 5.0%. The company is making a profit. +1
  • The TTM is 5.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ5.0%TTM5.0%0.0%
TTM5.0%YOY6.3%-1.3%
TTM5.0%5Y12.5%-7.5%
5Y12.5%10Y14.5%-2.0%
1.1.2. Return on Assets

Shows how efficient Yifan Xinfu Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • 1.5% Return on Assets means that Yifan Xinfu Pharmaceutical Co Ltd generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.5%0.0%
TTM1.5%YOY2.3%-0.8%
TTM1.5%5Y5.6%-4.0%
5Y5.6%10Y7.0%-1.5%
1.1.3. Return on Equity

Shows how efficient Yifan Xinfu Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • 2.2% Return on Equity means Yifan Xinfu Pharmaceutical Co Ltd generated ¥0.02 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 2.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM2.2%0.0%
TTM2.2%YOY3.3%-1.1%
TTM2.2%5Y8.0%-5.8%
5Y8.0%10Y10.7%-2.7%

1.2. Operating Efficiency of Yifan Xinfu Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Yifan Xinfu Pharmaceutical Co Ltd is operating .

  • Measures how much profit Yifan Xinfu Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 4.3% means the company generated ¥0.04  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 4.3%. The company is operating less efficient.
  • The TTM is 4.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ4.3%TTM4.3%0.0%
TTM4.3%YOY6.0%-1.6%
TTM4.3%5Y14.0%-9.7%
5Y14.0%10Y15.2%-1.1%
1.2.2. Operating Ratio

Measures how efficient Yifan Xinfu Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are ¥1.42 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 1.425. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.425. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.425TTM1.4250.000
TTM1.425YOY1.505-0.081
TTM1.4255Y1.380+0.044
5Y1.38010Y1.184+0.196

1.3. Liquidity of Yifan Xinfu Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Yifan Xinfu Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.68 means the company has ¥1.68 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 1.678. The company is able to pay all its short-term debts. +1
  • The TTM is 1.678. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.678TTM1.6780.000
TTM1.678YOY1.558+0.120
TTM1.6785Y1.529+0.149
5Y1.52910Y1.195+0.334
1.3.2. Quick Ratio

Measures if Yifan Xinfu Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.58 means the company can pay off ¥0.58 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 0.581. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.581. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.581TTM0.5810.000
TTM0.581YOY0.550+0.031
TTM0.5815Y0.496+0.085
5Y0.49610Y0.553-0.057

1.4. Solvency of Yifan Xinfu Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Yifan Xinfu Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.27 means that Yifan Xinfu Pharmaceutical Co Ltd assets are financed with 27.1% credit (debt) and the remaining percentage (100% - 27.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 0.271. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.271. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.271TTM0.2710.000
TTM0.271YOY0.279-0.008
TTM0.2715Y0.278-0.007
5Y0.27810Y0.318-0.041
1.4.2. Debt to Equity Ratio

Measures if Yifan Xinfu Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 38.6% means that company has ¥0.39 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The MRQ is 0.386. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.386. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.386TTM0.3860.000
TTM0.386YOY0.397-0.012
TTM0.3865Y0.399-0.014
5Y0.39910Y0.516-0.117

2. Market Valuation of Yifan Xinfu Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Yifan Xinfu Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Yifan Xinfu Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A PE ratio of 78.52 means the investor is paying ¥78.52 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The EOD is 77.044. Based on the earnings, the company is expensive. -2
  • The MRQ is 78.518. Based on the earnings, the company is expensive. -2
  • The TTM is 78.518. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD77.044MRQ78.518-1.474
MRQ78.518TTM78.5180.000
TTM78.518YOY78.107+0.411
TTM78.5185Y44.159+34.359
5Y44.15910Y152.037-107.878
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The EOD is -209.899. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -213.915. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -213.915. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-209.899MRQ-213.915+4.016
MRQ-213.915TTM-213.9150.000
TTM-213.915YOY-80.386-133.530
TTM-213.9155Y15.466-229.381
5Y15.46610Y187.669-172.203
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Yifan Xinfu Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.64 means the investor is paying ¥1.64 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Yifan Xinfu Pharmaceutical Co Ltd:

  • The EOD is 1.611. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.642. Based on the equity, the company is underpriced. +1
  • The TTM is 1.642. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.611MRQ1.642-0.031
MRQ1.642TTM1.6420.000
TTM1.642YOY2.478-0.836
TTM1.6425Y2.254-0.612
5Y2.25410Y9.840-7.586
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Yifan Xinfu Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3500.3500%0.039+793%0.386-9%0.707-50%
Book Value Per Share--7.4607.4600%7.110+5%6.717+11%4.713+58%
Current Ratio--1.6781.6780%1.558+8%1.529+10%1.195+40%
Debt To Asset Ratio--0.2710.2710%0.279-3%0.278-2%0.318-15%
Debt To Equity Ratio--0.3860.3860%0.397-3%0.399-3%0.516-25%
Dividend Per Share--0.0700.0700%0.112-37%0.179-61%0.119-41%
Eps--0.1560.1560%0.226-31%0.500-69%0.465-66%
Free Cash Flow Per Share---0.057-0.0570%-0.219+283%0.092-162%0.167-134%
Free Cash Flow To Equity Per Share---0.068-0.0680%-0.039-42%0.018-475%0.307-122%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.302--------
Intrinsic Value_10Y_min---4.221--------
Intrinsic Value_1Y_max--0.159--------
Intrinsic Value_1Y_min---0.097--------
Intrinsic Value_3Y_max--0.456--------
Intrinsic Value_3Y_min---0.576--------
Intrinsic Value_5Y_max--0.727--------
Intrinsic Value_5Y_min---1.362--------
Market Cap14736760015.360-2%15018804130.75015018804130.7500%21744949076.740-31%18670860661.790-20%24151881644.175-38%
Net Profit Margin--0.0500.0500%0.063-21%0.125-60%0.145-66%
Operating Margin--0.0430.0430%0.060-27%0.140-69%0.152-71%
Operating Ratio--1.4251.4250%1.505-5%1.380+3%1.184+20%
Pb Ratio1.611-2%1.6421.6420%2.478-34%2.254-27%9.840-83%
Pe Ratio77.044-2%78.51878.5180%78.107+1%44.159+78%152.037-48%
Price Per Share12.020-2%12.25012.2500%17.620-30%15.150-19%19.660-38%
Price To Free Cash Flow Ratio-209.899+2%-213.915-213.9150%-80.386-62%15.466-1483%187.669-214%
Price To Total Gains Ratio28.586-2%29.13329.1330%116.434-75%41.504-30%83.565-65%
Quick Ratio--0.5810.5810%0.550+6%0.496+17%0.553+5%
Return On Assets--0.0150.0150%0.023-33%0.056-73%0.070-78%
Return On Equity--0.0220.0220%0.033-33%0.080-73%0.107-80%
Total Gains Per Share--0.4200.4200%0.151+178%0.565-26%0.826-49%
Usd Book Value--1263096249.5051263096249.5050%1211766526.490+4%1142374485.785+11%800633690.391+58%
Usd Book Value Change Per Share--0.0480.0480%0.005+793%0.053-9%0.098-50%
Usd Book Value Per Share--1.0301.0300%0.982+5%0.928+11%0.651+58%
Usd Dividend Per Share--0.0100.0100%0.015-37%0.025-61%0.016-41%
Usd Eps--0.0220.0220%0.031-31%0.069-69%0.064-66%
Usd Free Cash Flow---9695884.112-9695884.1120%-37357169.596+285%15603579.561-162%28217743.026-134%
Usd Free Cash Flow Per Share---0.008-0.0080%-0.030+283%0.013-162%0.023-134%
Usd Free Cash Flow To Equity Per Share---0.009-0.0090%-0.005-42%0.002-475%0.042-122%
Usd Market Cap2035146558.121-2%2074096850.4572074096850.4570%3002977467.498-31%2578445857.393-20%3335374855.061-38%
Usd Price Per Share1.660-2%1.6921.6920%2.433-30%2.092-19%2.715-38%
Usd Profit--26415402.16226415402.1620%38446895.136-31%85041190.744-69%78895551.806-67%
Usd Revenue--529840094.444529840094.4440%608887814.406-13%648094904.708-18%499376860.467+6%
Usd Total Gains Per Share--0.0580.0580%0.021+178%0.078-26%0.114-49%
 EOD+3 -5MRQTTM+0 -0YOY+18 -175Y+10 -2510Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of Yifan Xinfu Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1577.044
Price to Book Ratio (EOD)Between0-11.611
Net Profit Margin (MRQ)Greater than00.050
Operating Margin (MRQ)Greater than00.043
Quick Ratio (MRQ)Greater than10.581
Current Ratio (MRQ)Greater than11.678
Debt to Asset Ratio (MRQ)Less than10.271
Debt to Equity Ratio (MRQ)Less than10.386
Return on Equity (MRQ)Greater than0.150.022
Return on Assets (MRQ)Greater than0.050.015
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Yifan Xinfu Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.668
Ma 20Greater thanMa 5011.207
Ma 50Greater thanMa 10011.561
Ma 100Greater thanMa 20013.054
OpenGreater thanClose11.530
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets12,543,503
Total Liabilities3,397,260
Total Stockholder Equity8,811,485
 As reported
Total Liabilities 3,397,260
Total Stockholder Equity+ 8,811,485
Total Assets = 12,543,503

Assets

Total Assets12,543,503
Total Current Assets3,689,927
Long-term Assets8,853,576
Total Current Assets
Cash And Cash Equivalents 1,143,784
Short-term Investments 95,502
Net Receivables 1,181,360
Inventory 830,971
Other Current Assets 249,705
Total Current Assets  (as reported)3,689,927
Total Current Assets  (calculated)3,501,323
+/- 188,605
Long-term Assets
Property Plant Equipment 1,601,383
Goodwill 2,737,767
Intangible Assets 3,298,742
Long-term Assets Other 143,019
Long-term Assets  (as reported)8,853,576
Long-term Assets  (calculated)7,780,912
+/- 1,072,664

Liabilities & Shareholders' Equity

Total Current Liabilities2,199,403
Long-term Liabilities1,197,857
Total Stockholder Equity8,811,485
Total Current Liabilities
Short Long Term Debt 659,260
Accounts payable 288,403
Other Current Liabilities 304,499
Total Current Liabilities  (as reported)2,199,403
Total Current Liabilities  (calculated)1,252,162
+/- 947,241
Long-term Liabilities
Long term Debt 850,168
Capital Lease Obligations Min Short Term Debt80,694
Long-term Liabilities Other 2,449
Long-term Liabilities  (as reported)1,197,857
Long-term Liabilities  (calculated)933,311
+/- 264,546
Total Stockholder Equity
Retained Earnings 4,754,600
Total Stockholder Equity (as reported)8,811,485
Total Stockholder Equity (calculated)4,754,600
+/- 4,056,885
Other
Capital Stock1,046,318
Common Stock Shares Outstanding 1,226,025
Net Debt 365,644
Net Invested Capital 10,320,912
Net Tangible Assets 5,322,346
Net Working Capital 1,490,525
Property Plant and Equipment Gross 1,601,383



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-31
> Total Assets 
87,368
131,961
199,035
358,700
516,945
582,355
884,417
856,266
1,140,462
1,201,429
1,166,251
1,061,539
1,060,985
3,334,689
4,546,737
6,983,504
8,767,730
9,774,884
11,065,800
11,637,240
12,165,125
12,543,503
12,543,50312,165,12511,637,24011,065,8009,774,8848,767,7306,983,5044,546,7373,334,6891,060,9851,061,5391,166,2511,201,4291,140,462856,266884,417582,355516,945358,700199,035131,96187,368
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,519,001
2,410,519
3,653,734
3,695,487
3,520,321
3,506,077
3,585,487
3,689,927
3,689,9273,585,4873,506,0773,520,3213,695,4873,653,7342,410,5191,519,00100000000000000
       Cash And Cash Equivalents 
14,152
21,421
8,637
101,608
46,495
69,620
96,334
51,060
228,478
156,130
145,076
125,846
124,184
277,705
332,220
729,491
1,308,854
1,627,297
1,523,667
1,323,777
1,336,144
1,143,784
1,143,7841,336,1441,323,7771,523,6671,627,2971,308,854729,491332,220277,705124,184125,846145,076156,130228,47851,06096,33469,62046,495101,6088,63721,42114,152
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,000
197,500
680,000
10,082
39,000
46,733
0
95,502
95,502046,73339,00010,082680,000197,50047,00000000000000000
       Net Receivables 
17,541
26,571
50,019
49,765
62,289
95,368
163,366
64,930
90,197
85,342
108,609
201,090
210,173
504,554
609,647
907,062
1,067,044
1,073,783
1,120,890
1,005,286
1,265,249
1,181,360
1,181,3601,265,2491,005,2861,120,8901,073,7831,067,044907,062609,647504,554210,173201,090108,60985,34290,19764,930163,36695,36862,28949,76550,01926,57117,541
       Other Current Assets 
1,742
84
303
5,163
19,395
18,522
57,086
54,136
77,006
44,947
46,976
28,349
12,067
158,849
161,645
199,969
205,626
380,994
238,578
319,353
320,223
249,705
249,705320,223319,353238,578380,994205,626199,969161,645158,84912,06728,34946,97644,94777,00654,13657,08618,52219,3955,163303841,742
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,572,985
5,113,996
6,079,397
7,545,479
8,131,163
8,579,638
8,853,576
8,853,5768,579,6388,131,1637,545,4796,079,3975,113,9964,572,985000000000000000
       Property Plant Equipment 
41,146
64,008
118,080
165,763
259,776
285,917
395,898
472,688
564,708
651,503
603,345
542,094
557,996
672,661
838,509
820,015
909,576
1,104,240
1,240,356
1,454,187
1,642,844
1,601,383
1,601,3831,642,8441,454,1871,240,3561,104,240909,576820,015838,509672,661557,996542,094603,345651,503564,708472,688395,898285,917259,776165,763118,08064,00841,146
       Goodwill 
0
0
0
0
3,558
3,177
0
0
0
0
0
0
0
1,242,659
1,819,040
2,394,505
2,413,261
2,645,166
2,727,685
2,749,671
2,737,767
2,737,767
2,737,7672,737,7672,749,6712,727,6852,645,1662,413,2612,394,5051,819,0401,242,65900000003,1773,5580000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,758
9,843
117,542
43,740
0
0
0
0
000043,740117,5429,8432,75800000000000000
       Intangible Assets 
958
897
837
776
4,216
11,802
6,701
8,183
4,380
0
0
0
0
1,386,865
231,228
1,211,947
1,466,598
2,018,690
2,583,570
2,869,162
3,091,431
3,298,742
3,298,7423,091,4312,869,1622,583,5702,018,6901,466,5981,211,947231,2281,386,86500004,3808,1836,70111,8024,216776837897958
       Other Assets 
0
0
188
0
0
0
72,011
58,426
75,964
70,665
68,843
69,630
67,452
50,827
136,201
1,083,406
1,358,645
1,884,714
2,102,521
2,508,941
2,900,700
3,066,369
3,066,3692,900,7002,508,9412,102,5211,884,7141,358,6451,083,406136,20150,82767,45269,63068,84370,66575,96458,42672,01100018800
> Total Liabilities 
35,054
52,529
104,725
48,721
196,016
267,919
335,871
285,393
227,314
497,788
696,731
580,726
553,340
791,214
1,666,167
3,082,950
1,985,460
2,887,212
3,244,093
2,907,012
3,390,566
3,397,260
3,397,2603,390,5662,907,0123,244,0932,887,2121,985,4603,082,9501,666,167791,214553,340580,726696,731497,788227,314285,393335,871267,919196,01648,721104,72552,52935,054
   > Total Current Liabilities 
35,054
52,529
73,879
46,476
196,016
267,519
335,690
285,393
219,987
409,070
688,908
578,188
536,139
756,801
1,428,501
2,568,441
1,586,629
2,396,236
2,883,317
2,128,946
2,301,840
2,199,403
2,199,4032,301,8402,128,9462,883,3172,396,2361,586,6292,568,4411,428,501756,801536,139578,188688,908409,070219,987285,393335,690267,519196,01646,47673,87952,52935,054
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,221,133
754,127
1,305,525
1,784,417
0
0
0
0001,784,4171,305,525754,1271,221,133000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,221,133
754,127
1,305,525
1,784,417
1,193,087
1,005,082
659,260
659,2601,005,0821,193,0871,784,4171,305,525754,1271,221,133000000000000000
       Accounts payable 
5,224
5,643
16,773
7,657
18,161
32,311
24,404
26,004
30,852
51,388
98,698
103,746
93,624
301,937
326,100
370,321
251,216
416,964
418,993
381,188
350,864
288,403
288,403350,864381,188418,993416,964251,216370,321326,100301,93793,624103,74698,69851,38830,85226,00424,40432,31118,1617,65716,7735,6435,224
       Other Current Liabilities 
450
2,506
6,726
15,819
34,855
17,208
102,286
34,389
19,135
7,682
44,210
18,784
25,842
149,151
243,340
399,415
293,326
397,304
455,387
356,081
277,545
304,499
304,499277,545356,081455,387397,304293,326399,415243,340149,15125,84218,78444,2107,68219,13534,389102,28617,20834,85515,8196,7262,506450
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
514,509
398,830
490,977
360,776
778,067
1,088,727
1,197,857
1,197,8571,088,727778,067360,776490,977398,830514,509000000000000000
       Other Liabilities 
0
0
846
2,245
0
400
0
0
7,327
8,718
7,823
2,538
17,201
17,838
207,666
334,509
274,830
457,122
275,602
329,488
268,421
0
0268,421329,488275,602457,122274,830334,509207,66617,83817,2012,5387,8238,7187,3270040002,24584600
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,341
990,320
1,193,237
1,659,844
1,900,578
2,187,265
2,473,612
0
02,473,6122,187,2651,900,5781,659,8441,193,237990,32014,34100000000000000
> Total Stockholder Equity
52,313
79,433
94,310
309,979
320,089
314,436
548,546
570,873
913,148
695,598
466,521
480,813
507,645
2,544,163
2,858,084
3,524,579
6,468,495
6,623,949
7,499,564
8,439,869
8,535,175
8,811,485
8,811,4858,535,1758,439,8697,499,5646,623,9496,468,4953,524,5792,858,0842,544,163507,645480,813466,521695,598913,148570,873548,546314,436320,089309,97994,31079,43352,313
   Common Stock
21,900
37,500
37,500
52,500
68,250
68,250
191,100
191,100
220,420
220,420
220,420
220,420
220,420
260,613
260,613
921,092
1,027,268
1,027,268
1,057,198
1,054,971
1,054,400
0
01,054,4001,054,9711,057,1981,027,2681,027,268921,092260,613260,613220,420220,420220,420220,420220,420191,100191,10068,25068,25052,50037,50037,50021,900
   Retained Earnings 
25,738
32,295
43,041
70,679
78,708
70,246
278,281
296,736
304,959
85,365
0
0
0
450,153
766,695
1,427,426
2,622,449
2,877,096
3,659,867
4,504,830
4,712,192
4,754,600
4,754,6004,712,1924,504,8303,659,8672,877,0962,622,4491,427,426766,695450,15300085,365304,959296,736278,28170,24678,70870,67943,04132,29525,738
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,579
13,342
15,345
30,875
28,838
-34,225
-92,357
0
0-92,357-34,22528,83830,87515,34513,3427,57900000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,038,056
Cost of Revenue-2,086,885
Gross Profit1,951,1711,951,171
 
Operating Income (+$)
Gross Profit1,951,171
Operating Expense-3,702,346
Operating Income335,710-1,751,175
 
Operating Expense (+$)
Research Development235,172
Selling General Administrative1,157,376
Selling And Marketing Expenses-
Operating Expense3,702,3461,392,548
 
Net Interest Income (+$)
Interest Income24,977
Interest Expense-76,096
Other Finance Cost-39,437
Net Interest Income-90,555
 
Pretax Income (+$)
Operating Income335,710
Net Interest Income-90,555
Other Non-Operating Income Expenses-
Income Before Tax (EBT)92,311335,710
EBIT - interestExpense = -76,096
134,867
210,963
Interest Expense76,096
Earnings Before Interest and Taxes (EBIT)-168,407
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax92,311
Tax Provision-14,309
Net Income From Continuing Ops78,00278,002
Net Income134,867
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-90,555
 

Technical Analysis of Yifan Xinfu Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Yifan Xinfu Pharmaceutical Co Ltd. The general trend of Yifan Xinfu Pharmaceutical Co Ltd is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Yifan Xinfu Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Yifan Xinfu Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 11.61 < 12.77 < 12.99.

The bearish price targets are: 11.61 > 10.87 > 10.74.

Tweet this
Yifan Xinfu Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Yifan Xinfu Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Yifan Xinfu Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Yifan Xinfu Pharmaceutical Co Ltd. The current macd is -0.10657749.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Yifan Xinfu Pharmaceutical Co Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Yifan Xinfu Pharmaceutical Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Yifan Xinfu Pharmaceutical Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Yifan Xinfu Pharmaceutical Co Ltd. The current adx is 14.54.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Yifan Xinfu Pharmaceutical Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Yifan Xinfu Pharmaceutical Co Ltd. The current sar is 10.85.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Yifan Xinfu Pharmaceutical Co Ltd. The current rsi is 59.67. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Yifan Xinfu Pharmaceutical Co Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Yifan Xinfu Pharmaceutical Co Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartYifan Xinfu Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Yifan Xinfu Pharmaceutical Co Ltd. The current cci is 269.50.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Yifan Xinfu Pharmaceutical Co Ltd. The current cmo is 33.83.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Yifan Xinfu Pharmaceutical Co Ltd. The current willr is -9.30232558.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Williams %R ChartYifan Xinfu Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Yifan Xinfu Pharmaceutical Co Ltd.

Yifan Xinfu Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Yifan Xinfu Pharmaceutical Co Ltd. The current atr is 0.43605229.

Yifan Xinfu Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Yifan Xinfu Pharmaceutical Co Ltd. The current obv is 191,821,264.

Yifan Xinfu Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartYifan Xinfu Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Yifan Xinfu Pharmaceutical Co Ltd. The current mfi is 53.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Yifan Xinfu Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartYifan Xinfu Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Yifan Xinfu Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Yifan Xinfu Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Yifan Xinfu Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.668
Ma 20Greater thanMa 5011.207
Ma 50Greater thanMa 10011.561
Ma 100Greater thanMa 20013.054
OpenGreater thanClose11.530
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Yifan Xinfu Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Yifan Xinfu Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Yifan Xinfu Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Yifan Xinfu Pharmaceutical Co Ltd

I send you an email if I find something interesting about Yifan Xinfu Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Yifan Xinfu Pharmaceutical Co Ltd.

Receive notifications about Yifan Xinfu Pharmaceutical Co Ltd in your mailbox!